Trevi Therapeutics Inc 2024年度报告

Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes☐No☒ Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ Accelerated filer☐ Smaller reporting company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any newor revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internalcontrol over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm thatprepared or issued its audit report.☐ If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in thefiling reflect the correction of an error to previously issued financial statements.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation receivedby any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of June 28, 2024, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting andnon-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq StockMarket, was $179.7 million. The number of shares of Registrant’s Common Stock outstanding as of March 14, 2025 was 96,682,229.DOCUMENTS INCORPORATED BY REFERENCEPortions of the Proxy Statement for the registrant’s 2025 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K. CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks anduncertainties. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K,including statements regarding our strategy, future operations, future financial position, future revenues and profitability,projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,”“believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,”“should,” “target,” “would,” and similar expressions are intended to identify forward-looking statements, although not allforward-looking statements contain these identifying words. The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: •our clinical trials, including our ongoing Phase 2b CORAL clinical trial and our planned Phase 3 program ofHaduvio for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, or IPF, our ongoingPhase 1b TIDAL study to evaluate the effect of Haduvio on respiratory physiology in patients with IPF ofvarying disease severity, our planned Phase 2 clinical trial of Haduvio for the treatment of chronic cough inpatients with non-IPF interstitial lung disease or non-IPF ILD, and our next clinical trial of Haduvio for thetreatment of patients with refractory chronic cough or RCC;•our plans to develop and, if approved, subsequently commercialize Haduvio for the treatment of chronic coughin patients with IPF, chronic cough in patients with non-IPF ILD and RCC;•our expectations regarding the timing for the initiation of clinical trials and the report